论文部分内容阅读
目的:了解2010~2015年浙江省11家医院肺癌患者5-HT_3受体拮抗药的应用情况和趋势,促进其合理用药。方法:抽取2010~2015年浙江省11家医院肺癌患者的医嘱用药数据,对其用药金额、用药频度(DDDs)、限定日费用(DDC)进行回顾性分析。结果:2010~2015年,浙江省11家医院肺癌患者使用5-HT_3受体拮抗药的用药金额逐年上升,但在总金额中的占比呈下降趋势,而2015年5-HT_3受体拮抗药不论用药金额还是占总用药金额比例都有所升高。6年内使用金额比例排名首位的分别为托烷司琼(2010~2014年)和帕洛诺司琼(2015年)。5-HT_3受体拮抗药DDDs排名首位是托烷司琼(2010~2015年),DDC排名首位为帕洛诺司琼。结论:浙江省11家医院肺癌患者使用的5-HT_3受体拮抗药基本合理,安全有效、经济方便的5-HT_3受体拮抗药在临床使用中占优势。
Objective: To understand the application and trend of 5-HT_3 receptor antagonist in lung cancer patients in 11 hospitals in Zhejiang province from 2010 to 2015, and to promote its rational use. Methods: Data of medical orders of lung cancer patients from 11 hospitals in Zhejiang province from 2010 to 2015 were collected and retrospectively analyzed on the amount of medication, DDDs and DDC. Results: From 2010 to 2015, the amount of 5-HT 3 receptor antagonist used in patients with lung cancer in 11 hospitals in Zhejiang Province increased year by year, but its proportion in the total amount showed a decreasing trend. In 2015, 5-HT 3 receptor antagonist Regardless of the amount of medication or the proportion of the total amount of medication have increased. Top in the amount of money used in the six years were tropisetron (2010-2014) and palonosetron (2015). DDDs, the top 5-HT 3 receptor antagonist, are tropisetron (2010-2015) and palonosetron is the first DDC. CONCLUSION: The 5-HT 3 receptor antagonist used in 11 lung cancer patients in Zhejiang province is reasonable, safe and effective, and the 5-HT 3 receptor antagonist is predominant in clinical use.